In this issue:
Managing IPF in clinical practice
Mortality for endpoint in IPF trials
Collagen degradation biomarker changes in IPF
Role of bacteria in IPF pathogenesis/progression
Effect of telomere length on IPF survival
Safety and pharmacokinetics of nintedanib and pirfenidone
Oral immunotherapy with type V collagen in IPF
IPF patients’ perceptions, experiences and needs
Palliative care and death location in decedents with IPF
Clinical features of LAM
Dyspnoea, health-related QOL and psychological factors in sarcoidosis
Analysing breath sounds in diffuse parenchymal lung disease
Please login below to download this issue (PDF)